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Introduction: Pegylated Interferon Alpha (Peg-IFN) in combination with other drugs is
the standard treatment for chronic hepatitis C infection (HCV) and is related to severe
painful symptoms. The aim of this study was access the efficacy of transcranial direct
current stimulation (tDCS) in controlling the painful symptoms related to Peg-IFN side
effects.
Materials and Methods: In this phase II double-blind trial, twenty eight (n = 28) HCV
subjects were randomized to receive either 5 consecutive days of active tDCS (n = 14)
or sham (n = 14) during 5 consecutive days with anodal stimulation over the primary
motor cortex region using 2mA for 20min. The primary outcomes were visual analogue
scale (VAS) pain and brain-derived neurotrophic factor (BDNF) serum levels. Secondary
outcomes were the pressure-pain threshold (PPT), the Brazilian Profile of Chronic Pain:
Screen (B-PCP:S), and drug analgesics use.
Results: tDCS reduced the VAS scores (P < 0.003), with a mean pain drop of 56%
(p < 0.001). Furthermore, tDCS was able to enhance BDNF levels (p < 0.01). The mean
increase was 37.48% in the active group. Finally, tDCS raised PPT (p < 0.001) and
reduced the B-PCP:S scores and analgesic use (p < 0.05).
Conclusions: Five sessions of tDCS were effective in reducing the painful symptoms
in HCV patients undergoing Peg-IFN treatment. These findings support the efficacy of
tDCS as a promising therapeutic tool to improve the tolerance of the side effects related
to the use of Peg-IFN. Future larger studies (phase III and IV trials) are needed to confirm
the clinical use of the therapeutic effects of tDCS in such condition.
Trial registration: Brazilian Human Health Regulator for Research with the approval
number CAAE 07802012.0.0000.5327.
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INTRODUCTION
Hepatitis C virus (HCV) is the major cause of chronic liver
disease, with an estimation of 160–170 million infected people
around the world. If not treated appropriately, it can leads
to severe consequences, such as development of hepatocellular
carcinoma, cirrhosis, and liver failure. In spite of the advent
of first-wave generation direct-acting antivirals (DAAs), like
telaprevir and boceprevir, the associated use Pegylated Interferon
(Peg-INF) in combination with ribavirin and/or protease
inhibitors represents the current best therapy recommendation
for chronic HCV (Kohli et al., 2014; EASL, 2015).
One of the most relevant extrahepatic adverse outcome is
the presence of neurovegetative symptoms. Classically, they
are represented by fast and progressive pain development
[headaches, myalgia, arthralgia, fatigue, and psychomotor
slowing] (Loftis and Hauser, 2004; Huckans et al., 2015) which
typically continues over the treatment. The control of pain is
often neglected in such patients and is strongly related to a
decrease in life-quality and treatment interruption (Louie et al.,
2012; Zhanga et al., 2015). The main causes of neurovegetative
symptoms are still unclear. Nonetheless, it is a decrease of brain-
derived neurotrophic factor (BDNF) in HCV patients treated
with Peg-INF (Kenis et al., 2011). BDNF is a neurotrophic
factor that is ubiquitously distributed in the CNS and has
been recognized as an important marker of neuronal plasticity
and is associated with chronic pain. It has a critical role in
sensitization and its associated neuroplasticity due to changing
excitatory/inhibitory balance in the CNS and increases pain
neurotransmission through modulation of nociceptive inputs as
well (Chassot et al., 2015). Serum BDNF levels have been shown
to be inversely associated with pressure-pain threshold (PPT) in
fibromyalgia (Zanette et al., 2014). Similarly, BDNF is negatively
correlated with pain scores in chronic myofascial pain syndrome
(Dall’Agnol et al., 2014).
Transcranial direct current stimulation (tDCS) is a non-
invasive brain stimulation that has revealed promising results in
the management of several diseases (Antal et al., 2008; Hansen
et al., 2010; Lindenberg et al., 2010; Borckardt et al., 2011;
Dasilva et al., 2012; Knotkova et al., 2012; Kumru et al., 2013). It
modulates cortical excitability by a low electrical current applied
to the brain through electrodes placed on the scalp (Nitsche and
Paulus, 2000; Fregni et al., 2005; Dieckhöfer et al., 2006). tDCS
has several advantages such as safety, low-cost, and few adverse
effects. Moreover, the unique role in controlling and relieving
pain has an important clinical role since many RCTs have shown
its efficacy in addressing this issue (Nitsche et al., 2007; Wagner
et al., 2007).
The mechanisms underlying the side effects induced by Peg-
INF are related to neuroinflammatory and neuroplasticity
processes. New therapies that can counteract on such
mechanisms to guarantee the continuity and optimizing Peg-INF
treatment are of utmost importance for a better management of
HCV patients (Loftis and Hauser, 2004; Kohli et al., 2014; EASL,
2015; Huckans et al., 2015). Therefore, in order to provide new
insights into the neurobiology of the painful symptoms related to
Peg-INF in chronic HCV, we performed a phase II randomized
clinical trial, double blind, to access whether tDCS could control
such symptoms. Moreover, we also hypothesized that tDCS can
modulate important neuroplasticity markers in HCV patients,
such as BDNF.
MATERIALS AND METHODS
The current study was designed according to the CONSORT
guidelines for transparent reporting of trials. The methodological
background chart of the study is shown in Figure 1.
Study Design and Eligibility
This phase II randomized, double-blind, sham-controlled, two-
arm parallel design, was conducted at one single center study in
Hospital de Clínicas de Porto Alegre (Rio Grande do Sul, Brazil).
The study was reviewed and approved by the IRB (IRB from the
Hospital de Clínicas de Porto Alegre—HCPA/UFRGS/Approval
number: 154.287) and conducted in accordance with the
Declaration of Helsinki Principles. Written informed consent
was obtained from all participants. The trial was registered at
the Brazilian Human Health Regulator for Research with the
approval number CAAE 07802012.0.0000.5327 (Platform Brazil,
aplicacao.saude.gov.br/plataformabrasil/login.jsf).
The studied enrolled 80 subjects in according to the following
parameters: (i) Diagnosis of chronic C hepatitis (according to the
detection of anti-HCV antibodies and HCV RNA in the presence
of histological or biological signs of chronic hepatitis). (ii)
Current treatment with Peg-INF in combination with ribavirin
and/or protease inhibitors.
Inclusion and Exclusion Criteria
In order to be a part of the study, the subjects had to fulfill all
of the following inclusion criteria: (i) Age range between 18 and
75 years. (ii) Pain VAS scores ≥ 4. (iii) Presence of depression
(assessed by Beck Depression Inventory) for at least 3 months
prior of enrollment. (iv) Statement of daily activities limitations
(absence from work, decrease of social skills, loss of emotional
involvement in routine activities, lack of personal goals, and
restriction in cognitive abilities, such as loss of concentrating and
memory) related to HCV infection. Participants were excluded if
they met the following parameters: (i) History of liver transplant.
(ii) Presence of any metal object or implant in brain, skull, scalp,
or neck. (iii) Implantable devices, including cardiac pacemakers
and defibrillators. (iv) Pregnancy. (v) Morbidly obesity (BMI
above 40). (vi) HIV infection. (vii) History of alcohol or substance
abuse in the past 6 months. After applying the inclusion and
exclusion criteria, 31 patients were excluded. Moreover, 21
patients declined participating due to difficulty in accessing the
hospital according to the required study protocol. A final sample
size of 28 subjects was randomized.
Randomization, Allocation Concealment,
Implementation, and Masking
Randomized numbers in a 1:1 ratio were generated using
appropriate software (www.randomization.com) to assign each
participant to either active or sham-placebo group. The patients
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FIGURE 1 | Randomization and follow-up of the study subjects.
were randomized in blocks of four without stratification.
Envelopes were prepared for randomization process and sealed.
After subject’s agreement to participate in the trial, one
investigator who was not involved with either stimulation or
assessments opened the envelope. The allocation concealment
was reached since no investigator (stimulators nor accessors)
was aware of treatment allocations and had no control over
the order of patients randomized. During the entire protocol
timeline, two investigators were responsible for the blinding and
randomization procedures.
Intervention
tDCS was delivered using the anode electrode positioned over
the left primary motor cortex (M1) and the cathode electrode
at supra orbital right region. The electrodes were placed into
a 25–35 cm2 square sponge immersed in saline solution for
better current conductivity. Current density used was 2mA and
electrodes attached to the scalp were sustained by rubber band.
The stimulation period was based on previous studies and the
protocol used was 20min for 5 consecutive days (Boggio et al.,
2009; Valle et al., 2009; Knotkova et al., 2012).
Supplementary Analgesic Use
Patients were allowed to use supplementary analgesic drugs
(acetaminophen, dipyrone) to relieve their pain if necessary.
They we asked to record their analgesic intake during the
treatment period in pain diaries. The total analgesic dose took
during the treatment period was considered for the analysis.
Instruments and Assessments
The psychological tests used in this study had been validated for
the Brazilian population (Babor et al., 1989; Kaipper et al., 2010;
Sehn et al., 2012; Warmenhoven et al., 2012; Caumo et al., 2013).
Two independent blinded examiners were trained to apply the
pain scales and to conduct the psychological tests. The baseline
depressive symptoms of the patients were assessed using the
Beck Depression Inventory (Warmenhoven et al., 2012). The
screening test for alcohol misuse is the Alcohol Use Disorders
Identification Test (AUDIT) was used to screen for all types of
alcohol misuse, i.e., hazardous drinking, harmful drinking, and
dependence (Babor et al., 1989).
Outcomes and Assessments
The primary outcomes were VAS pain scores and BDNF serum
levels. Secondary outcomes were the PPT and the change of the
pain assessed by Brazilian Profile of Chronic Pain: Screen (B-
PCP:S) which represents the validated Portuguese version Profile
of Chronic Pain: Screen (PCP:S).
Assessment of Outcomes
(i) The intensity of pain was measured by the visual analog
scale (VAS). The VAS scores ranged from no pain (zero) to
the worst possible pain (Dall’Agnol et al., 2014). Patients were
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asked to rate their level of pain during related to the last 24 h
before the treatment every single day. As soon as the stimulation
finished, they were asked to rate again the pain level using
VAS scale. (ii) The B-PCP:S in order to identify the individual’s
multidimensional pain experience. The B-PCP:S addressees three
dimensions related to pain (severity, interference, and emotional
burden) and it was applied at baseline and at the end of treatment.
(iii) PPT. The PPT was examined (baseline and after final
session) using an algometer device (JTECH Medical Industries,
Salt Lake City, UT). The algometer’s 1 cm2 hard-rubber probe
was pressed against the right antecubital fossa with constant
increasing pressure. The procedure stopped as soon as the patient
indicated uncomfortable pain pressure. (iv) Serum levels of
BDNF. Blood samples were collected at baseline and by the end of
treatment. Serum BDNF was determined by the Enzyme-Linked
Immunoabsorbent Assay (ELISA) using a ChemiKine BDNF
Sandwich ELISA Kit, CYT306 (Chemicon/Millipore, Billerica,
MA, USA). The lower detection limit of the kit is 7.8 pg/mL
for BDNF.
Sample Size Method and Statistical
Analysis
An a priori estimation indicated a sample size of 24 patients
divided into two groups (n = 12) in order to detect a 1.5 cm
reduction (average standard deviation 0.8 cm) in pain VAS level
intensity with a power and α levels of 0.8 and 0.025, respectively.
Such a reduction would be clinically relevant and comparable to
other pharmacological interventions (Vidor et al., 2012; Caumo
et al., 2013; Schwertner et al., 2013). To account for multiple
outcomes and considering an attrition rate around 30%, the
sample size was increased to 14 patients per group.
The continuous and categorical variables were summarized
using conventional descriptive statistics. The t-test, chi-square
or Fisher’s exact tests were used to compare the continuous
and the categorical variables, respectively. For non-parametric
distributions, group comparisons were performed using the
Wilcoxon-Mann-Whitney test. Daily values recorded in the pain
scales were averaged to generate one value for each intervention
week. The normality assumption for the VAS and the B-PCP:S
was tested using the skewness and kurtosis tests. To analyze the
effect of the intervention on the VAS, we conducted a group
analysis by running a mixed ANOVAmodel. If appropriate, post-
hoc analyses considering Bonferroni’s adjustment for multiple
comparisons were performed. We calculated the adjusted mean
differences to access efficacy. The confidence intervals (95% CI)
and associated P-values were calculated. The standardized mean
difference (SMD) was computed in terms of the ratio between
the mean change and the placebo-sham standard deviation. The
SMD (also known as the effect size) was interpreted as follows:
small (≤ 0.40); moderate (0.41–0.79); and high (≥0.80) (Middel
and van Sonderen, 2002). An intention-to-treat (ITT) analysis
was performed, with the last observation carried forward. The
serum BDNF was log transformed and used as dependent
variable in a linear regression model including the experimental
group (placebo-sham and tDCS) and the cumulative pain score
on the VAS as independent variables. The data were analyzed
using SPSS, version 18.0 (SPSS, Chicago, IL).
RESULTS
Demographic and Clinical Characteristics
of the Subjects
A total of 80 subjects were enrolled in this study. After applying
the inclusion and exclusion criteria, 31 patients were excluded. In
addition, 21 patients declined to participate in the study due to
difficulty in accessing the hospital according to the study protocol
(5 consecutive days in a week). A final sample size of 28 subjects
was randomized. The clinical and demographic characteristics
of the patients are presented in Table 1. Fourteen patients were
allocated to either active tDCS or placebo-sham. Twenty five
patients completed the study; one dropout in the tDCS group
two dropouts in the sham group. Baseline features were balanced
between the studied groups (p > 0.05).
Analysis of the Primary Outcomes: VAS
Scores and Serum BDNF
The active-tDCS group had significantly lower pain VAS scores
(P < 0.003) starting at the second session until the end of
the treatment (Figure 2). The interaction between time and
treatment group was not significant (P = 0.07). There was no
interaction between time and the intervention group (P = 0.07).
The cumulative mean ± SD pain on the VAS was 1.68 ± 2.31 in
TABLE 1 | Baseline demographic and clinical characteristics of the patients at active or sham group.
Placebo-sham (n = 14) tDCS (n = 14) p-value
Education (years) 9.14 ± 3.14 9.43 ± 3.55 0.86
Age (years) 56.57 ± 8.52 53.86 ± 5.76 0.33
Gender M/F 12/2 9/5 0.2
Beck depression inventory 22.14 ± 7.81 24.57 ± 9.91 0.47
Profile of chronic pain: screen for a brazilian population (B-PCP:S) 70.58 ± 13.27 67.93 ± 12.65 0.49
Brain derived neurotrophic factor (BDNF) levels 13 (74) 13.83 (6.60) 0.36
11.72 (7.48–20.35) 12.03 (9.97–20.29)
Pain on visual analogue scale (VAS) 7.38 (1.19) 6.81 (1.81) 0.33
Pain pressure threshold (PPT) 4.42 (1.44) 2.77 (1.04) 0.18
Frontiers in Neuroscience | www.frontiersin.org 4 January 2016 | Volume 9 | Article 498
Brietzke et al. tDCS in HCV Painful Symptoms
FIGURE 2 | Pain VAS scores at baseline and during the treatment. The
error bars indicate the standard error of the mean (SEM). Asterisks (*)
positioned above the symbols indicate significant differences (p < 0.01) at
those time points using Anova model type III test.
FIGURE 3 | Mean serum BDNF levels at baseline and after treatment.
Asterisk (*) positioned above the symbols indicate significant differences
(p < 0.01).
the group receiving tDCS and 3.0 ± 2.74 in the placebo-sham.
The tDCS group had a mean pain reduction of 56% (P < 0.001)
compared with placebo-sham, representing a moderately sized
effect (Cohen’s d = 0.49).
Concerning BDNF, the tDCS group had a significantly higher
serum levels (P < 0.01) (Figure 3). The mean increase from
the baseline was 37.48% in the tDCS-active group, whereas
the placebo-sham group presented a mean reduction of 1.48%.
To address whether the BDNF reduction was secondary to
pain improvement or a primary effect of the intervention,
we conducted an additional regression model. The adjusted
mean difference in the BDNF level between the tDCS and the
placebo-sham groups was of 4.64 (95% CI = 2.3–7.07, P <
0.001). The interaction between the intervention group and pain
on the VAS was significant (P < 0.01), indicating that the
variability in the serum BDNF was related to the pain and the
intervention group. In stratifying by the intervention groups,
the effect of pain was significant for both groups (Table 2).
The correlation was inversed in the placebo-sham group, which
means that the pain increase was correlated with the lower
serum BDNF.
FIGURE 4 | Mean pain threshold at baseline and at the end of
treatment. The error bars indicate the standard error of the mean (SEM).
Asterisks (*) positioned above the symbols indicate significant differences
(p < 0.001).
Secondary Outcomes: PPT, Analgesic Use,
and B-PCP:S Score
In the active tDCS group, the adjusted mean (±SD) of the
PPT at the end of treatment was 3.97 ± 1.34 (43.32% mean
increase from baseline) as compared with 2.99 ± 1.11 (2.68%
mean reduction from baseline) (p = 0.007) (Figure 4). The end
of treatment PPT was adjusted for baseline levels (r-squared =
0.46, standard β coefficient for the baseline pain threshold= 0.79,
t = 4.01), standard β coefficient for the active-tDCS was 1.15
(placebo-sham was reference group), t = 2.97, both P < 0.001.
The B-PCP:S was lower in the tDCS group with 29.07 ± 9.20,
compared to 50.58 ± 14.33 in the placebo-sham group (P <
0.001). The mean difference at the end of the intervention was
21.50 [confidence interval (CI) 95% = 12.02–30.99], indicating
that the tDCS treatment effect size, on the B-PCP:S, was large (i.e.,
Cohen’s d = 1.50).
Analgesic use during the intervention period occurred in 63%
of the patients in the placebo-sham group and in 37% of the
patients in the active-tDCS group. The relative risk for using
analgesics during the 5 days of treatment was 1.43 (95% CI
1.04–1.96); the placebo-sham group was 43% more likely to
require additional analgesics. There was a significant reduction
in the number of analgesic doses for the patients receiving tDCS
compared to those receiving the placebo-sham (p < 0.03).
DISCUSSION
This current study showed that tDCS reduced the painful
symptoms induced by Peg-IFN in patients with chronic HCV
compared to a placebo-sham. The effect was statistically
significant and has clinical relevance taking into account
our findings. Moreover, tDCS treatment was associated with
increased BDNF serum levels and also with an improvement at
the PPT test. To our knowledge and based on a careful review
of the scientific literature (Pubmed, Web of science, Scopus, and
Isi) this is the first evidence showing tDCS positive effects in
controlling pain in HCV infected patients undergoing Peg-IFN
therapy.
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TABLE 2 | Multivariate linear regression of the pain reported compared with BDNF, treatment group and daily pain VAS (n = 24).
Parameter B T P-value 95% CI
DEPENDENT VARIABLE: SERUM BDNF IN THE END OF TREATMENT
Cumulative worst pain score on VAS diary (mean of 5 days) −1.54 −2.87 0.005 (−2.59 to −0.48)
Placebo-sham * (Cumulative worst pain score on VAS) vs. −0.49 −0.32 0.74 (−3.43 to 2.46)
Active-tDCS * (Cumulative worst pain score on VAS) vs.
Interaction 1.05 2.98 0.003 (0.35 to 1.74)
Cumulative worst pain score on VAS diary * (placebo-sham) −0.49 −2.0 0.02 (−0.98 to −0.04)
Cumulative worst pain score on VAS diary * (active-tDCS) 0.28 2.25 0.03 (0.03 to 0.52)
BDNF, brain derived neurotropic factor; VAS, visual analogue scale; CI, confidence interval.
Linear regression model—Adjusted R2 = 0.10.
*Numerical Pain Scale collected before and after tDCS during all days of treatment.
Asmentioned before, the mechanisms underlying the etiology
of Peg-IFN painful symptoms are not well known. It is believed
that a trigger activates the system network that stimulates the
central nervous system (CNS) inflammatory pathways (Raison
et al., 2009). The tDCS effect on pain might be related to
an interruption in the response associated with maladaptive
neuroplasticity, which induces neuroimmune reactions that
could amplify pain signals in the neural pain matrix (Xanthos
and Sandkühler, 2014). In addition, tDCS may inhibit microglial
activation observed in inflammatory diseases such as viral
infections and the neuroinflammatory reactions induced by Peg-
IFN (Par et al., 2013).
Our findings suggest that tDCS induces neuroplastic changes
in pain pathways, including modulation in neurotransmitters
that regulate pain (i.e., it increases the serum BDNF levels).
Especially, our results were related to the pain symptoms
status of the subjects indicating the clinical relevance of tDCS
therapy in such scenario. Some studies indicate that the Peg-
INF is responsible for activating CNS inflammatory pathways
by stimulating and releasing proinflammatory in both periphery
and CNS (Quan and Banks, 2007; Raison et al., 2009). The
relationship between the serum BDNF and pain in the current
study provides evidence of the role of Peg-IFN in the sensitization
of the CNS areas associated with nociceptive sensory processing.
Considering the increased level of BDNF expression in response
to higher levels of neuronal activity, it can be inferred a possible
relation with cortical activity that strengthens inhibitory synapses
for pain (Genoud et al., 2004). Hence, BDNF could act as a
molecular marker of global neuronal activity (Genoud et al.,
2004). These findings are in agreement with the tDCS clinical
effects demonstrated in the treatment of other types of chronic
pain due to different etiologies (Fregni et al., 2006a; Antal et al.,
2008; Fenton et al., 2009).
In addition, the decrease of the symptoms of central
sensitization induced by Peg-IFN, and its association with the
increase BDNF after 5 days of stimulation can lead to some other
deductions. For instance, the central sensitization was properly
modulated and this was not related to the use of common
analgesics. Finally, the tDCS could had reached effects not only
in CNS but also in periphery pain pathways, taking into account
that the sensitization is orchestrated by neuronal, endocrinal, and
immune mechanisms capable of amplifying sensory pain signals
to the neural pain matrix (Garcia-Larrea and Peyron, 2007).
In the present study, the tDCS analgesia was consistently
demonstrated by different outcomes: reduction on VAS pain
scores, decrease on analgesic drugs use, and PPT increase. It must
be highlighted that synaptic plasticity processes have a direct
connection with the primary somatosensory cortex network, like
the neuronal inactivation induced by stimulation of the M1 area.
The tDCS can also modulates other structures related to pain
facilitation such as the thalamus and the brainstem nuclei, which
down regulate processing from the sensitized neurons (Polanía
et al., 2011). The tDCS device was operated with a ramp up
of 15 s while starting the stimulation (either sham or active)
and a ramp down of 15 s during the end of the procedure. A
decrease in mean pain scores (3.0 ± 2.74) seen in the placebo-
sham group was observed, in spite of a significantly higher
reduction in pain scores reported by the tDCS group. Taking into
account such findings, it can be mentioned that the placebo effect
was detected in our study and that even with sham stimulation
the subjects experienced an improvement in pain symptoms
(Wechsler et al., 2011). While there is some evidence that placebo
interventions can alter levels of hormones (Kokkotou et al.,
2010), endocannabinoids or endogenous opioids (Benedetti et al.,
2005), other reasons could be related to the Hawthorne effect,
regression to the mean and etc. (Barnett et al., 2005).
The strengths of the study include the study design and the
major concern of running a RCT that could cover as most
as possible the clinical research requirements for high quality
trials. The comparison between active tDCS and a placebo-sham
intervention in a randomized, two-arm parallel, double blinded,
properly masking, and allocation concealment must be stressed.
Furthermore, multiple efficacy outcomes gives support to our
findings toward the effect of the tDCS and enabled a better
knowledge underlying its mechanisms of action. Nonetheless,
this study has some limitations. Although the BDNF is secreted
by neurons and neuroglia in the CNS (Savli et al., 2004), it actively
crosses the blood-brain barrier, contributing to 70–80% of its
serum concentration (Schinder and Poo, 2000).We did not assess
the possible influence of BDNF polymorphisms on this sample,
and theymight have an influence in neuronal plasticity. The short
follow-up period is another limitation of the current study that
Frontiers in Neuroscience | www.frontiersin.org 6 January 2016 | Volume 9 | Article 498
Brietzke et al. tDCS in HCV Painful Symptoms
should be mentioned. Our study design and framework (2mA,
20min, 5 consecutive days, M1 target) were based on parameters
reported by some previous studies (Fregni et al., 2006a; Boggio
et al., 2009; Valle et al., 2009; Knotkova et al., 2012; Sakrajai et al.,
2014; Souto et al., 2014; Fagerlund et al., 2015). One interesting
study evaluated the tDCS effect for reducing pain due to spinal
cord injury and the cumulative analgesic effects lasted up to 2
weeks after stimulation (Fregni et al., 2006a). The same protocol
was adopted in two studies with fibromyalgia and a significant
improvement in pain was detected following active tDCS (Fregni
et al., 2006b; Fagerlund et al., 2015). In one of these studies, the
pain relief effects lasted up to 3 weeks (Fregni et al., 2006b).
A recent study using tDCS to reduce myofascial pain (Sakrajai
et al., 2014) was able to reduce the pain symptoms and the
effects persisted 1 week after the final tDCS session. Considering
these data on the lasting effects of tDCS regarding pain relief
(2 weeks in average), it can be hypothesized that patients with
HCV hepatitis receiving Peg-IFN should have 5 consecutive
sessions every 15 days. Further studies with a well-designed
follow-up period are needed to evaluate the long lasting effects
of tDCS for pain improvement in HCV subjects undergoing
Peg-INF treatment. Such data would bring valuable knowledge
strengthening the use of tDCS in clinical practice.
To sum up, we have demonstrated the clinical efficacy of tDCS
in relieving pain, the increase on PPT increase and BDNF serum
levels and the reduction of analgesic use in chronic HCV infected
patients receiving Peg-INF. From a clinical standpoint, these
findings support the use of tDCS as a promising therapeutic tool
to improve the tolerance of the side effects related to the use of
Peg-IFN and further studies (phase III and IV trials) are required
in order to allow the clinical use of tDCS in as a valid treatment
in these patients.
AUTHOR CONTRIBUTIONS
AB, JR had substantial contributions to the conception or design
of the work. AD, GL, JD, PH drafting the work or revising
it critically for important intellectual content. WC, Rd had
final approval of the version to be published. SM, Id, MA,
FF agreement to be accountable for all aspects of the work
in ensuring that questions related to the accuracy or integrity
of any part of the work are appropriately investigated and
resolved.
ACKNOWLEDGMENTS
The present research was supported by the following Brazilian
funding agencies: (i) Committee for the Development of Higher
Education Personnel—CAPES (grant to JR with Postdoctorade
sholarship, Grant # 023/2011; AB, JD, AD, GL, PH). (ii) National
Council for Scientific and Technological Development - CNPq
(grant to Dr. Id, Dr. WC). (iii) Post graduate Program in
Medical Sciences of Medical School of the Federal University of
Rio Grande do Sul. (iv) Post graduate Research Group at the
Hospital de Clínicas de Porto Alegre (SM,MA). (v) Laboratory of
Neuromodulation & Center for Clinical Research Learning (Rd,
FF). (vi) Foundation for Support of Research at Rio Grande do
Sul (FAPERGS).
REFERENCES
Antal, A., Brepohl, N., Poreisz, C., Boros, K., Csifcsak, G., and Paulus, W. (2008).
Transcranial direct current stimulation over somatosensory cortex decreases
experimentally induced acute pain perception. Clin. J. Pain 24, 56–63. doi:
10.1097/AJP.0b013e318157233b
Babor, T. F., de la Fuente, J. R., Saunders, J., and Grant, M. (1989). AUDIT: The
Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Health
Care. Geneva: World Health Organization.
Barnett, A. G., van der Pols, J. C., Dobson, A. J. (2005). Regression to the
mean: what it is and how to deal with it. Int. J. Epidemiol. 34, 215–220. doi:
10.1093/ije/dyh299
Benedetti, F., Mayberg, H. S., Wager, T. D., Stohler, C. S., and
Zubieta, J. K. (2005). Neurobiological mechanisms of the placebo
effect. J. Neurosci. 25, 10390–10402. doi: 10.1523/JNEUROSCI.3458-
05.2005
Boggio, P. S., Zaghi, S., and Fregni, F. (2009). Modulation of emotions
associated with images of human pain using anodal transcranial
direct current stimulation (tDCS). Neuropsychologia 47, 212–217. doi:
10.1016/j.neuropsychologia.2008.07.022
Borckardt, J. J., Romagnuolo, J., Reeves, S. T., Madan, A., Frohman, H., Beam, W.,
et al. (2011). Feasibility, safety, and effectiveness of transcranial direct current
stimulation for decreasing post-ERCP pain: a randomized, sham-controlled,
pilot study. Gastrointest. Endosc. 73, 1158–1164. doi: 10.1016/j.gie.2011.
01.050
Caumo, W., Torres, F., Moreira, N. L. Jr., Auzani, J. A., Monteiro, C. A.,
Londero, G., et al. (2013). The clinical impact of preoperative melatonin on
postoperative outcomes in patients undergoing abdominal hysterectomy.
Anesth. Analg. 105, 1263–1271. doi: 10.1213/01.ane.0000282834.78
456.90
Chassot, M., Dussan-Sarria, J. A., Sehn, F. C., Deitos, A., de Souza, A., Vercelino,
R., et al. (2015). Electroacupuncture analgesia is associated with increased
serum brain-derived neurotrophic factor in chronic tension-type headache: a
randomized, sham controlled, crossover trial. BMC Complement. Altern. Med.
15:144. doi: 10.1186/s12906-015-0664-x
Dall’Agnol, L., Medeiros, L. F., Torres, I. L., Deitos, A., Brietzke, A., Laste,
G., et al. (2014). Repetitive transcranial magnetic stimulation increases the
corticospinal inhibition and the brain-derived neurotrophic factor in chronic
myofascial pain syndrome: an explanatory double-blinded, randomized,
sham-controlled trial. J. Pain. 15, 845–855. doi: 10.1016/j.jpain.2014.
05.001
Dasilva, A. F., Mendonca, M. E., Zaghi, S., Lopes, M., Dossantos, M. F., Spierings,
E. L., et al. (2012). tDCS-induced analgesia and electrical fields in pain-
related neural networks in chronic migraine. Headache 52, 1283–1295. doi:
10.1111/j.1526-4610.2012.02141.x
Dieckhöfer, A., Waberski, T. D., Nitsche, M., Paulus, W., Buchner, H.,
and Gobbelé, R. (2006). Transcranial direct current stimulation applied
over the somatosensory cortex - differential effect on low and high
frequency SEPs.Clin. Neurophysiol. 117, 2221–2227. doi: 10.1016/j.clinph.2006.
07.136
EASL (2015). EASL recommendations on treatment of hepatitis C. J. Hepatol. 63,
199–236. doi: 10.1016/j.jhep.2015.03.025
Fagerlund, A. J., Hansen, O. A., and Aslaksen, P. M. (2015). Transcranial
direct current stimulation as a treatment for patients with fibromyalgia: a
randomized controlled trial. Pain 156, 62–71. doi: 10.1016/j.pain.00000000000
00006
Fenton, B. W., Palmieri, P. A., Boggio, P., Fanning, J., and Fregni, F. (2009).
A preliminary study of transcranial direct current stimulation for the
treatment of refractory chronic pelvic pain. Brain Stimul. 2, 103–107. doi:
10.1016/j.brs.2008.09.009
Frontiers in Neuroscience | www.frontiersin.org 7 January 2016 | Volume 9 | Article 498
Brietzke et al. tDCS in HCV Painful Symptoms
Fregni, F., Boggio, P. S., Lima, M. C., Ferreira, M. J., Wagner, T., Rigonatti, S. P.,
et al. (2006a). A sham-controlled, phase II trial of transcranial direct current
stimulation for the treatment of central pain in traumatic spinal cord injury.
Pain 122, 197–209. doi: 10.1016/j.pain.2006.02.023
Fregni, F., Boggio, P. S., Nitsche, M., Bermpoh, F., Antal, A., Feredoes, E., et al.
(2005). Anodal transcranial direct current stimulation of prefrontal cortex
enhances working memory. Exp. Brain Res. 166, 23–30. doi: 10.1007/s00221-
005-2334-6
Fregni, F., Gimenes, R., Valle, A. C., Ferreira, M. J., Rocha, R. R., Natalle,
L., et al. (2006b). A randomized, sham-controlled, proof of principle study
of transcranial direct current stimulation for the treatment of pain in
fibromyalgia. Arthritis Rheum. 54, 3988–3998. doi: 10.1002/art.22195
Garcia-Larrea, L., and Peyron, R. (2007). Motor cortex stimulation for neuropathic
pain: from phenomenology to mechanisms.Neuroimage 37(Suppl. 1), S71–S79.
doi: 10.1016/j.neuroimage.2007.05.062
Genoud, C., Knott, G. W., Sakata, K., Lu, B., and Welker, E. (2004). Altered
synapse formation in the adult somatosensory cortex of brain-derived
neurotrophic factor heterozygote mice. J. Neurosci. 24, 2394–2400. doi:
10.1523/JNEUROSCI.4040-03.2004
Hansen, N., Obermann, M., Poitz, F., Holle, D., Diener, H. C., Antal, A.,
et al. (2010). Modulation of human trigeminal and extracranial nociceptive
processing by transcranial direct current stimulation of the motor cortex.
Cephalalgia 31, 661–670. doi: 10.1177/0333102410390394
Huckans, M., Fuller, B., Wheaton, V., Jaehnert, S., Ellis, C., Kolessar, M., et al.
(2015). A longitudinal study evaluating the effects of interferon-alpha therapy
on cognitive and psychiatric function in adults with chronic hepatitis C.
J. Psychosom. Res. 78, 184–192. doi: 10.1016/j.jpsychores.2014.07.020
Kaipper, M. B., Chachamovich, E., Hidalgo, M. P., Torres, I. L., and Caumo, W.
(2010). Evaluation of the structure of Brazilian State-Trait Anxiety Inventory
using a Rasch psychometric approach. J. Psychosom. Res. 68, 223–233. doi:
10.1016/j.jpsychores.2009.09.013
Kenis, G., Prickaerts, J., van Os, J., Koek, G. H., Robaeys, G., Steinbusch,
H. W., et al. (2011). Depressive symptoms following interferon-α therapy:
mediated by immune- et al. Induced reductions in brain-derived neurotrophic
factor? Int. J. Neuropsychopharmacol. 14, 247–253. doi: 10.1017/S14611457100
00830
Knotkova, H., Rosedale, M., Strauss, S. M., Horne, J., Soto, E., Cruciani, R. A., et al.
(2012). Using transcranial direct current stimulation to treat depression inHIV-
infected persons: the outcomes of a feasibility study. Front. Psychiatry 3:59. doi:
10.3389/fpsyt.2012.00059
Kohli, A., Shaffer, A., Sherman, A., and Kottilil, S. (2014). Treatment of
hepatitis C: a systematic review. J. Am. Med. Assoc. 312, 631–640. doi:
10.1001/jama.2014.7085
Kokkotou, E., Conboy, L. A., Ziogas, D. C., Quilty, M. T., Kelley, J. M., Davis, R. B.,
et al. (2010). Serum correlates of the placebo effect in irritable bowel syndrome.
Neurogastroenterol. Motil. 22, 285–e81. doi: 10.1111/j.1365-2982.2009.
01440.x
Kumru, H., Soler, D., Vidal, J., Navarro, X., Tormos, J. M., and Pascual-Leone,
A. (2013). The effects of transcranial direct current stimulation with visual
illusion in neuropathic pain due to spinal cord injury: an evoked potentials and
quantitative thermal testing study. Eur. J. Pain. 17, 55–66. doi: 10.1002/j.1532-
2149.2012.00167.x
Lindenberg, R., Renga, V., Zhu, L. L., Nair, D., and Schlaug, G. (2010).
Bihemispheric brain stimulation facilitates motor recovery in chronic
stroke patients. Neurology 75, 2176–2184. doi: 10.1212/WNL.0b013e3182
02013a
Loftis, J. M., and Hauser, P. (2004). The phenomenology and treatment
of interferon-induced depression. J. Affect. Disord. 15, 175–190. doi:
10.1016/j.jad.2004.04.002
Louie, K. S., St Laurent, S., Forssen, U.M.,Mundy, L.M., and Pimenta, J. M. (2012).
The high comorbidity burden of the hepatitis C virus infected population
in the United States. BMC Infect. Dis. 12:86. doi: 10.1186/1471-2334-
12-86
Middel, B., and van Sonderen, E. (2002). Statistical significant change
versus relevant or important change in (quasi) experimental design:
some conceptual and methodological problems in estimating magnitude
of intervention-related change in health services research. Int. J. Integr.
Care 2:e15.
Nitsche, M. A., Doemkes, S., Karaköse, T., Antal, A., Liebetanz, D., Lang,
N., et al. (2007).Shaping the effects of transcranial direct current
stimulation ofthe human motor cortex. J. Neurophysiol. 97, 3109–3117.
doi: 10.1152/jn.01312.2006
Nitsche, M. A., and Paulus, W. (2000). Excitability changes induced
in the human motor cortex by weak transcranial direct current
stimulation. J. Physiol. 527, 633–639. doi: 10.1111/j.1469-7793.2000.t01-1-
00633.x
Par, G., Szereday, L., Berki, T., Palinkas, L., Halasz, M., Miseta, A., et al.
(2013). Increased baseline proinflammatory cytokine production in chronic
hepatitis C patients with rapid virological response to peginterferon
plus ribavirin. PLoS ONE 8:e67770. doi: 10.1371/journal.pone.00
67770
Polanía, R., Nitsche, M. A., and Paulus, W. (2011). Modulating
functional connectivity patterns and topological functional
organization of the human brain with transcranial direct current
stimulation. Hum. Brain Mapp. 32, 1236–1249. doi: 10.1002/hbm.
21104
Quan, N., and Banks, W. A. (2007). Brain-immune communication
pathways. Brain Behav. Immun. 21, 727–735. doi: 10.1016/j.bbi.2007.
05.005
Raison, C. L., Borisov, A. S., Majer, M., Drake, D. F., Pagnoni, G., Woolwine, B. J.,
et al. (2009). Activation of central nervous system inflammatory pathways by
interferonalpha: relationship to monoamines and depression. Biol. Psychiatry
65, 296–303. doi: 10.1016/j.biopsych.2008.08.010
Sakrajai, P., Janyacharoen, T., Jensen, M. P., Sawanyawisuth, K., Auvichayapat,
N., and Tunkamnerdthai, O., et al. (2014). Pain reduction in myofascial pain
syndrome by anodal transcranial direct current stimulation combined with
standard treatment: a randomized controlled study.Clin. J. Pain 30, 1076–1083.
doi: 10.1097/AJP.0000000000000069
Savli, H., Gulkac, M. D., and Esen, N. (2004). The effect of stimulated
microglia conditioned media on BDNF gene expression of striatal astrocytes:
quantification by real-time PCR. Int. J. Neurosci. 114, 1601–1612. doi:
10.1080/00207450490476138
Schinder, A. F., and Poo, M. (2000). The neurotrophin hypothesis for
synaptic plasticity. Trends Neurosci. 23, 639–645. doi: 10.1016/S0166-2236(00)
01672-6
Schwertner, A., Conceição Dos Santos, C. C., Costa, G. D., Deitos, A., de Souza,
A., de Souza, I. C., et al. (2013). Efficacy of melatonin in the treatment of
endometriosis: a phase II, randomized, double-blind, placebo-controlled trial.
Pain 154, 874–881. doi: 10.1016/j.pain.2013.02.025
Sehn, F., Chachamovich, E., Vidor, L. P., Dall-Agnol, L., de Souza, I. C., Torres,
I. L., et al. (2012). Cross-cultural adaptation and validation of the Brazilian
Portuguese version of the pain catastrophizing scale. Pain Med. 13, 1425–1435.
doi: 10.1111/j.1526-4637.2012.01492.x
Souto, G., Borges, I. C., Goes, B. T., de Mendonça, M. E., Gonçalves, R. G., Garcia,
L. B., et al. (2014). Effects of tDCS-induced motor cortex modulation on pain
in HTLV-1: a blind randomized clinical trial. Clin. J. Pain 30, 809–815. doi:
10.1097/AJP.0000000000000037
Valle, A., Roizenblatt, S., Botte, S., Zaghi, S., Riberto, M., Tufik, S., et al.
(2009). Efficacy of anodal transcranial direct current stimulation (tDCS)
for the treatment of fibromyalgia: results of a randomized, sham-controlled
longitudinal clinical trial. J. Pain Manag. 2, 353–361.
Vidor, L. P., Torres, I. L., Custódio de Souza, I. C., Fregni, F., and
Caumo, W. (2012). Analgesic and sedative effects of melatonin in
temporomandibular disorders: a double-blind, randomized, parallel-group,
placebo-controlled study. J. Pain Symptom Manage. 46, 422–432. doi:
10.1016/j.jpainsymman.2012.08.019
Wagner, T., Valero-Cabre, A., and Pascual-Leone, A. (2007). Noninvasive
human brain stimulation. Annu. Rev. Biomed. Eng. 9, 527–565. doi:
10.1146/annurev.bioeng.9.061206.133100
Warmenhoven, F., van Rijswijk, E., Engels, Y., Kan, C., Prins, J., van Weel, C.,
et al. (2012). The Beck Depression Inventory (BDI-II) and a single screening
question as screening tools for depressive disorder in Dutch advanced cancer
patients. Support Care Cancer 20, 319–324. doi: 10.1007/s00520-010-1082-8
Wechsler, M. E., Kelley, J. M., Boyd, I. O., Dutile, S., Marigowda, G., Kirsch, I.,
et al. (2011). Active albuterol or placebo, sham acupuncture, or no intervention
in asthma. N. Engl. J. Med. 365, 119–126. doi: 10.1056/NEJMoa1103319
Frontiers in Neuroscience | www.frontiersin.org 8 January 2016 | Volume 9 | Article 498
Brietzke et al. tDCS in HCV Painful Symptoms
Xanthos, D. N., and Sandkühler, J. (2014). Neurogenic neuroinflammation:
inflammatory CNS reactions in response to neuronal activity. Nat. Rev.
Neurosci. 15, 43–53. doi: 10.1038/nrn3617
Zanette, S. A., Dussan-Sarria, J. A., Souza, A., Deitos, A., Torres, I. L., and
Caumo, W. (2014). Higher serum S100B and BDNF levels are correlated
with a lower pressure-pain threshold in fibromyalgia. Mol. Pain. 8;10:46. doi:
10.1186/1744-8069-10-46
Zhanga, S., Rusta, G., Cardarellib, K., Felizzolac, J., Fransuad, M., Stringer,
H. G. Jr. (2015). Adherence to highly active antiretroviral therapy impact
on clinical and economic outcomes for Medicaid enrollees with human
immunodeficiency virus and hepatitis C coinfection. AIDS Care. 27, 829–835.
doi: 10.1080/09540121.2015.1021745
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Brietzke, Rozisky, Dussan-Sarria, Deitos, Laste, Hoppe, Muller,
Torres, Alvares-da-Silva, de Amorim, Fregni and Caumo. This is an open-access
article distributed under the terms of the Creative Commons Attribution License
(CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Neuroscience | www.frontiersin.org 9 January 2016 | Volume 9 | Article 498
